Trial of Autologous Mesenchymal Stem Cells in Patients With Multiple System Atrophy

Yonsei University27 enrolled

Overview

This study is based on positive results in open label trial of mesenchymal stem cells therapy in patients with Multiple System Atrophy (MSA).

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

Conditions

Multiple System Atrophy

Interventions

autologous mesenchymal stem cellsBIOLOGICAL

4\*107 stem cell (100ml) Intra arterial infusion/ one time, then 4\*107 stem cell(100ml)Intravenous infusion 3 times/monthly -\> Total four times

normal salineBIOLOGICAL

saline

Eligibility

Sex: ALLMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * 75 Years Old or Less * Multiple System Atrophy * Voluntary Participants Exclusion Criteria: * Doubted dementia (MMSE \< 24) * Severe febrile condition * Serum SGOT/SGPT three times above * Malignant mass

Locations (1)

Severance Hospital

Seoul, South Korea

Outcomes

Primary Outcomes

Scores on unified MSA rating scale

The statistical difference between scores before and after autologous mesenchymal stem cells treatment of unified MSA rating scale will be measured every month and every year using paired t-test.

Time frame: one month

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.